Breakthrough for Psychedelic Medicine - Rick Doblin, Ph.D.

MDMA-assisted psychotherapy offers a transformative approach to treating PTSD when conventional methods fail. Clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) demonstrate that a significant majority of participants no longer meet the diagnostic criteria for PTSD following a brief course of MDMA-assisted treatment, with sustained results observed at 12-month follow-ups. This therapeutic model has received breakthrough therapy designation from the FDA, acknowledging the potential for MDMA to address unmet patient needs through a novel mechanism of action. The ongoing expansion of these studies in the US and Europe necessitates the scalable training of new therapists to support the wider implementation of this clinical protocol.